Coya Therapeutics has achieved an important regulatory milestone with U.S. FDA acceptance of an Investigational New Drug (IND) application for COYA 302, marking the advancement of a promising new treatment approach for frontotemporal dementia (FTD), a devastating neurodegenerative disorder with no approved disease-modifying therapies.
FTD represents a significant public health challenge, particularly for younger populations. As the most common form of dementia in people under age 65, it affects approximately 60,000 Americans with an average onset age of 58 and median survival time of 7.5 years. The disease progressively destroys cognitive and behavioral functions, causing memory problems, impaired reasoning, executive dysfunction, emotional changes, and loss of empathy that severely interfere with daily living. Currently, no treatment exists to slow or reverse disease progression, creating a substantial unmet medical need.
According to BusinessWire.com, COYA 302 represents a novel therapeutic approach targeting the underlying inflammatory mechanisms believed to drive FTD. The investigational biologic combines two components: low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig, administered subcutaneously. This dual-mechanism therapy is specifically designed to enhance the anti-inflammatory function of regulatory T cells (Tregs)—immune cells critical for maintaining immune balance—while simultaneously suppressing inflammation produced by activated monocytes and macrophages. The combination may produce additive or synergistic anti-inflammatory effects.
The scientific rationale for this approach is compelling. Growing evidence implicates neuroinflammation as a key driver of FTD progression. By restoring proper immune regulation through enhanced Treg function, COYA 302 aims to interrupt the inflammatory cascade underlying the disease. Dr. Fred Grossman, Chief Medical Officer at Coya, emphasized this connection: “There is growing evidence for the relationship between neuroinflammation and progression of FTD. We believe the dual mechanism of COYA 302, which is designed to enhance the anti-inflammatory function of Tregs, provides a strong scientific rationale for evaluating this therapy in patients with FTD.”
The FDA acceptance of the IND application represents validation of the scientific approach and opens the pathway for human clinical trials. Leading neurologist Dr. Adam Boxer, Professor of Neurology at UCSF and recognized FTD clinical trials expert, endorsed this development: “There is a great need to develop disease modifying treatments for patients with FTD since none exist today. I am pleased to see this new treatment approach with a strong scientific rationale being moved forward toward a clinical trial for sporadic FTD.”
Coya’s broader therapeutic platform leverages multiple approaches to restore Treg function, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. COYA 302 is currently being evaluated in the ALSTARS trial for amyotrophic lateral sclerosis (ALS), another neurodegenerative condition, and the company previously announced an investigator-initiated open-label study evaluating the drug combination in mild-to-moderate FTD patients, with topline results expected in coming weeks.
This FDA milestone reflects growing recognition that immune dysfunction, particularly impaired regulatory T cell function, plays a fundamental role in neurodegenerative disease progression. The advancement of COYA 302 into formal clinical development offers hope that immunomodulatory approaches targeting neuroinflammation could finally provide disease-modifying treatment for FTD patients facing an otherwise relentless disease.
